English | Español

Innovent Biologics, Inc.
Press release submission | Jul 3, 2022

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Press release submission | Mar 20, 2019

INNOVENT BIOLOGICS, INC. : Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
Press release submission | Feb 27, 2019

INNOVENT BIOLOGICS, INC.: First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma

Trending
Patient Daily | Sep 3, 2025

Top healthcare marketing experts to present at AOCOO-HNS 2025 virtual mid-year symposium, led by Greg Caesar of Medfluence Advisors
+ Pharmaceuticals
Patient Daily | Sep 4, 2025

PhRMA CEO on 340B abuse: ‘Big hospitals are abusing the 340B program to markup medicine prices’
+ Pharmaceuticals
Patient Daily | Sep 2, 2025

Fmr. Gov. Dean on 340B: ‘There's no actual requirement for hospitals to pass along the savings’
+ Pharmaceuticals
Patient Daily | Aug 29, 2025

Deputy VP of Public Affairs of PhRMA on 340B: ‘Over 80% of all rural hospital beds were actually in urban hospitals’